Tetracycline suppresses ATPγS-induced CXCL8 and CXCL1 production by the human dermal microvascular endothelial cell-1 (HMEC-1) cell line and primary human dermal microvascular endothelial cells

Experimental Dermatology

Volumn 17, Issue 9, 2008, Pages 752-760

  Bender, Anna ^a   Zapolanski, Tamar ^a   Watkins, Shannon ^a   Khosraviani, Ava ^a   Seiffert, Kristina ^a   Ding, Wanhong ^a   Wagner, John A ^a   Granstein, Richard D ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Adenosine triphosphate; Chemokines; Cytokines; Endothelial cells; Tetracycline

Indexed keywords

CXCL1 CHEMOKINE; INTERLEUKIN 8; TETRACYCLINE; TRYPAN BLUE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL COUNT; CELL STRAIN; CELL STRAIN HUMAN DERMAL MICROVASCULAR ENDOTHELIAL CELL 1; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; SKIN BLOOD VESSEL; SKIN INFLAMMATION; VASCULAR ENDOTHELIUM;

ADENOSINE TRIPHOSPHATE; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; CELL LINE, TRANSFORMED; CELL SURVIVAL; CHEMOKINE CXCL1; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; HUMANS; HYDROCORTISONE; INTERLEUKIN-8; MICROVESSELS; PENICILLINS; PROTEIN SYNTHESIS INHIBITORS; SKIN; TETRACYCLINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 49049116575     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2008.00716.x     Document Type: Article

References (49)

1. Golub L M, Ciancio S, Ramamamurthy N S, Leung M, McNamara T F. Low-dose doxycycline therapy: Effect on gingival and crevicular fluid collagenase activity in humans. J Periodontal Res 1990: 25: 321-330.
2. Golub L M, Goodson J M, Lee H M, Vidal A M, McNamara T F, Ramamurthy N S. Tetracyclines inhibit tissue collagenases. Effects of ingested low-dose and local delivery systems. J Periodontol 1985: 56: 93-97.
3. Golub L M, Lee H M, Lehrer G et al. Minocycline reduces gingival collagenolytic activity during diabetes. Preliminary observations and a proposed new mechanism of action. J Periodontal Res 1983: 18: 516-526.
4. Golub L M, Wolff M, Lee H M et al. Further evidence that tetracyclines inhibit collagenase activity in human crevicular fluid and from other mammalian sources. J Periodontal Res 1985: 20: 12-23.
5. Golub L M, Lee H M, Ryan M E, Giannobile W V, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998: 12: 12-26.
6. Burns F R, Stack M S, Gray R D, Paterson C A. Inhibition of purified collagenase from alkali-burned rabbit corneas. Invest Ophthalmol Vis Sci 1989: 30: 1569-1575.
7. Choi D H, Moon I S, Choi B K et al. Effects of sub-antimicrobial dose doxycycline therapy on crevicular fluid MMP-8, and gingival tissue MMP-9, TIMP-1 and IL-6 levels in chronic periodontitis. J Periodontal Res 2004: 39: 20-26.
8. Thomas J, Walker C, Bradshaw M. Long-term use of subantimicrobial dose doxycycline does not lead to changes in antimicrobial susceptibility. J Periodontol 2000: 71: 1472-1483.
9. Sapadin A N, Fleischmajer R. Tetracyclines: Nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006: 54: 258-265.
10. Tsankov N, Broshtilova V, Kazandjieva J. Tetracyclines in dermatology. Clin Dermatol 2003: 21: 33-39.
11. Weinberg J M. The anti-inflammatory effects of tetracyclines. Cutis 2005: 75: 6-11.
12. Kloppenburg M, Dijkmans B A, Breedveld F C. Antimicrobial therapy for rheumatoid arthritis. Baillieres Clin Rheumatol 1995: 9: 759-769.
13. Kloppenburg M, Dijkmans BA, Verweij C L, Breedveld F C. Inflammatory and immunological parameters of disease activity in rheumatoid arthritis patients treated with minocycline. Immunopharmacology 1996: 31: 163-169.
14. Langevitz P, Livneh A, Bank I, Pras M. Benefits and risks of minocycline in rheumatoid arthritis. Drug Saf 2000: 22: 405-414.
15. Brown D L, Desai K K, Vakili B A, Nouneh C, Lee H M, Golub L M. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler Thromb Vasc Biol 2004: 24: 733-738.
16. Berman B, Zell D. Subantimicrobial dose doxycycline: A unique treatment for rosacea. Cutis 2005: 75: 19-24.
17. Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA 1998: 95: 15769-15774.
18. Ryu J K, Franciosi S, Sattayaprasert P, Kim S U, McLarnon J G. Minocycline inhibits neuronal death and glial activation induced by beta-amyloid peptide in rat hippocampus. Glia 2004: 48: 85-90.
19. Wang X, Zhu S, Drozda M et al. Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci USA 2003: 100: 10483-10487.
20. Zhu S, Stavrovskaya I G, Drozda M et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002: 417: 74-78.
21. Popovic N, Schubart A, Goetz B D, Zhang S C, Linington C, Duncan I D. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol 2002: 51: 215-223.
22. Shapira L, Soskolne W A, Houri Y, Barak V, Halabi A, Stabholz A. Protection against endotoxic shock and lipopolysaccharide-induced local inflammation by tetracycline: Correlation with inhibition of cytokine secretion. Infect Immun 1996: 64: 825-828.
23. Richardson-Burns S M, Tyler K L. Minocycline delays disease onset and mortality in reovirus encephalitis. Exp Neurol 2005: 192: 331-339.
24. Nieman G F, Zerler B R. A role for the anti-inflammatory properties of tetracyclines in the prevention of acute lung injury. Curr Med Chem 2001: 8: 317-325.
25. Feldman S R, Hollar C B, Gupta A K, Fleischer A B Jr. Women commonly seek care for rosacea: Dermatologists frequently provide the care. Cutis 2001: 68: 156-160.
26. Litt J Z. Rosacea: How to recognize and treat an age-related skin disease. Geriatrics 1997: 52: 39-40, 42, 45-37.
27. Jansen T, Plewig G. Rosacea: Classification and treatment. J R Soc Med 1997: 90: 144-150.
28. Pelle M T, Crawford G H, James W D. Rosacea: II. Therapy. J Am Acad Dermatol 2004: 51: 499-512.
29. Sneddon I B. A clinical trial of tetracycline in rosacea. Br J Dermatol 1966: 78: 649-652.
30. Knight A G, Vickers C F. A follow-up of tetracycline-treated rosacea. With special reference to rosacea keratitis. Br J Dermatol 1975: 93: 577-580.
31. Skidmore R, Kovach R, Walker C et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol 2003: 139: 459-464.
32. Esterly N B, Koransky J S, Furey N L, Trevisan M. Neutrophil chemotaxis in patients with acne receiving oral tetracycline therapy. Arch Dermatol 1984: 120: 1308-1313.
33. Golub L M, McNamara T F, D'Angelo G, Greenwald R A, Ramamurthy N S. A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity. J Dent Res 1987: 66: 1310-1314.
34. Seiffert K, Ding W, Wagner J A, Granstein R D. ATPgammaS enhances the production of inflammatory mediators by a human dermal endothelial cell line via purinergic receptor signaling. J Invest Dermatol 2006: 126: 1017-1027.
35. Ades E W, Candal F J, Swerlick R A et al. HMEC-1: Establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 1992: 99: 683-690.
36. Swerlick R A, Lawley T J. Role of microvascular endothelial cells in inflammation. J Invest Dermatol 1993: 100: 111S-115S.
37. Goebeler M, Yoshimura T, Toksoy A, Ritter U, Bröcker E B, Gillitzer R. The chemokine repertoire of human dermal microvascular endothelial cells and its regulation by inflammatory cytokines. J Invest Dermatol 1997: 108: 445-451.
38. Eklund K K, Sorsa T. Tetracycline derivative CMT-3 inhibits cytokine production, degranulation, and proliferation in cultured mouse and human mast cells. Ann N Y Acad Sci 1999: 878: 689-691.
39. Kirkwood K L, Golub L M, Bradford P G. Non-antimicrobial and antimicrobial tetracyclines inhibit IL-6 expression in murine osteoblasts. Ann N Y Acad Sci 1999: 878: 667-670.
40. Kirkwood K, Martin T, Andreadis S T, Kim Y J. Chemically modified tetracyclines selectively inhibit IL-6 expression in osteoblasts by decreasing mRNA stability. Biochem Pharmacol 2003: 66: 1809-1819.
41. Akamatsu H, Asada M, Komura J, Asada Y, Niwa Y. Effect of doxycycline on the generation of reactive oxygen species: A possible mechanism of action of acne therapy with doxycycline. Acta Derm Venereol 1992: 72: 178-179.
42. Milano S, Arcoleo F, D'Agostino P, Cillari E. Intraperitoneal injection of tetracyclines protects mice from lethal endotoxemia downregulating inducible nitric oxide synthase in various organs and cytokine and nitrate secretion in blood. Antimicrob Agents Chemother 1997: 41: 117-121.
43. Amin A R, Patel R N, Thakker G D, Lowenstein C J, Attur M G, Abramson S B. Post-transcriptional regulation of inducible nitric oxide synthase mRNA in murine macrophages by doxycycline and chemically modified tetracyclines. FEBS Lett 1997: 410: 259-264.
44. Di Virgilio F, Chiozzi P, Ferrari D et al. Nucleotide receptors: An emerging family of regulatory molecules in blood cells. Blood 2001: 97: 587-600.
45. Krishnaswamy G, Kelley J, Yerra L, Smith J K, Chi D S. Human endothelium as a source of multifunctional cytokines: Molecular regulation and possible role in human disease. J Interferon Cytokine Res 1999: 19: 91-104.
46. Ciancio S G, Mather M L, McMullen J A. An evaluation of minocycline in patients with periodontal disease. J Periodontol 1980: 51: 530-534.
47. Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet 1988: 15: 355-366.
48. Pastore S, Mascia F, Gulinelli S et al. Stimulation of purinergic receptors modulates chemokine expression in human keratinocytes. J Invest Dermatol 2007: 127: 660-667.
49. Kwon Y B, Kim C D, Kim B J et al. Anti-angiogenic effect of tetraacetyl-phytosphingosine. Exp Dermatol 2007: 16: 311-317.